Open AccessOvulatlon Inhibitors Containing Cyproterone Acetate Or Desogestrel In The Treatment Of Hyperandrogenic Symptoms
Author(s) -
Erkkola R.,
Hirvonen E.,
Luikku J.,
Lumme R.,
Männikkö H.,
Avdinlik S.
Publication year - 1990
Publication title -
acta obstetricia et gynecologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.401
H-Index - 102
eISSN - 1600-0412
pISSN - 0001-6349
DOI - 10.3109/00016349009021041
Subject(s) - cyproterone acetate , medicine , desogestrel , acne , hirsutism , cyproterone , ethinylestradiol , gynecology , antiandrogen , libido , gastroenterology , dermatology , hormone , androgen , population , polycystic ovary , family planning , research methodology , insulin resistance , environmental health , insulin
An open, randomized, multicenter study was carried out to compare two oral contraceptives as regards their therapeutic efficacy in androgenization symptoms such as acne, seborrhea and hirsutism in women. The preparations used were the combination of 2 mg cyproterone acetate (CPA) with 0.035 mg ethinyl estradiol (EE) (Diane35®, Schering AG, Berlin‐West) and 0.150 mg desogestrel (DG) with 0.03 mg ethinyl estradiol (Marvelon®, Organon, Oss, The Netherlands). The duration of therapy was 9 months. The combination of CPA‐EE was used by 83 patients for 658 cycles and the combination of DG‐EE by 79 women for 618 cycles. No pregnancy occurred under either therapy. Both preparations are well tolerated. However, some side‐effects, such as reduced libido, nervousness and breast tenderness, were observed more frequently (p < 0.05) in the DG‐EE group than among the users of the CPA‐EE Combination. The therapeutic outcome was better in the CPA‐EE group, especially in cases of facial acne (p<0.05). Seborrheic symptoms also responded better to the CPA‐EE therapy. The results show that the CPA‐EE combination is superior to the DG‐EE combination in the treatment of acne and seborrhoea.